CBD shows early promise for both psychosis and addiction, especially in early-stage illness
A systematic review found CBD improved schizophrenia symptoms (particularly in early illness), showed positive effects on cannabis withdrawal and craving when combined with THC, and identified blood anandamide levels as a potential treatment response biomarker.
Quick Facts
What This Study Found
CBD as monotherapy or adjunct to antipsychotics improved symptoms in schizophrenia patients, with particularly promising effects in early-stage illness. For substance use disorders, CBD+THC mixtures showed positive effects on short-term cannabis withdrawal and craving. Blood anandamide levels emerged as a potential biomarker for CBD treatment response in psychosis.
Key Numbers
CBD improved psychosis symptoms in clinical studies, with stronger effects in early illness stages. CBD+THC reduced short-term cannabis withdrawal and craving. Anandamide blood levels identified as potential biomarker. No studies found on comorbid schizophrenia and substance use.
How They Did This
Systematic review of human clinical studies investigating CBD efficacy for schizophrenia, substance use disorders, and their comorbidity. Examined patient profiles most likely to benefit.
Why This Research Matters
CBD is unique among cannabinoids in potentially treating both psychosis and addiction, two conditions that frequently co-occur and are notoriously difficult to manage together. Identifying who benefits most could make CBD treatment more targeted and effective.
The Bigger Picture
The dual potential of CBD for psychosis and addiction could be transformative for patients who have both conditions, a common and treatment-resistant combination. The anandamide biomarker finding could enable precision medicine approaches.
What This Study Doesn't Tell Us
Limited number of clinical studies available. Most psychosis studies were small. Substance use disorder evidence mainly comes from cannabis use disorder, not other substances. No studies addressed the comorbidity directly.
Questions This Raises
- ?Will CBD work as well in chronic psychosis as in early illness?
- ?Can anandamide levels predict CBD response reliably?
- ?Will the early substance use disorder results replicate in larger trials?
Trust & Context
- Key Stat:
- Early-stage psychosis responds best
- Evidence Grade:
- Rated preliminary because while the systematic review methodology is rigorous, the underlying clinical studies are few and small.
- Study Age:
- Published in 2019. Additional clinical trials of CBD for psychosis and substance use disorders have been conducted since.
- Original Title:
- The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.
- Published In:
- Journal of clinical medicine, 8(7) (2019)
- Authors:
- Batalla, Albert(8), Janssen, Hella, Gangadin, Shiral S, Bossong, Matthijs G
- Database ID:
- RTHC-01936
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can CBD treat psychosis?
Early clinical evidence suggests CBD can improve schizophrenia symptoms, particularly in the early stages of illness, either alone or added to standard antipsychotic medication.
Does CBD help with cannabis addiction?
When combined with THC, CBD showed positive effects on reducing short-term withdrawal symptoms and craving in cannabis use disorder. Studies on other substance addictions are lacking.
What is the anandamide biomarker?
Anandamide is a natural endocannabinoid. Its blood levels may predict how well a patient will respond to CBD treatment for psychosis, potentially enabling more personalized treatment decisions.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01936APA
Batalla, Albert; Janssen, Hella; Gangadin, Shiral S; Bossong, Matthijs G. (2019). The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.. Journal of clinical medicine, 8(7). https://doi.org/10.3390/jcm8071058
MLA
Batalla, Albert, et al. "The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.." Journal of clinical medicine, 2019. https://doi.org/10.3390/jcm8071058
RethinkTHC
RethinkTHC Research Database. "The Potential of Cannabidiol as a Treatment for Psychosis an..." RTHC-01936. Retrieved from https://rethinkthc.com/research/batalla-2019-the-potential-of-cannabidiol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.